|
|
|
|
| LEADER |
01712nam a2200325 u 4500 |
| 001 |
EB001999914 |
| 003 |
EBX01000000000000001162815 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Iron isomaltoside 1000 (Monoferric) (Pharmacosmos A/S)
|h Elektronische Ressource
|b indication: for the treatment of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy
|
| 246 |
3 |
1 |
|a Iron isomaltoside 1000 (Monoferric) (Pharmacosmos A/S)
|
| 246 |
3 |
1 |
|a CADTH common drug review Clinical review report for iron isomaltoside 1000 (Monoferric)
|
| 250 |
|
|
|a Final
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2020, May 2020
|
| 300 |
|
|
|a 1 PDF file (99 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Disaccharides / therapeutic use
|
| 653 |
|
|
|a Adult
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Anemia, Iron-Deficiency / drug therapy
|
| 653 |
|
|
|a Ferric Compounds / therapeutic use
|
| 653 |
|
|
|a Treatment Outcome
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK564268
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of this review was to perform a systematic review of the beneficial and harmful effects of iron isomaltoside 1000 injection (100 mg elemental iron/ml) for the treatment of iron deficiency anemia in adults (greater than/equal to 18 years of age) who have an intolerance or unresponsiveness to oral iron
|